Alivus Life Sciences Limited — PPTs, 30-07-2026: Investor Presentation

Alivus Life Sciences delivered a strong Q1 FY27. Revenue reached ₹640.4 Cr, a 6.4% YoY increase, with PAT soaring 31.8% YoY to ₹160.1 Cr. EPS for the quarter was ₹13.04. This robust performance was largely driven by the non-GPL business, which jumped 26.5% YoY. Margins saw significant improvement, with EBITDA margin at 36.6% (up 650 bps YoY) and PAT margin at 25.0% (up 480 bps YoY).

Growth drivers include ramping up the CDMO segment and expanding into complex API platforms like oncology and HP API. The company is actively pursuing capacity expansion with brownfield projects at Ankleshwar (~100KL by Q4 FY27) and Dahej (~160KL by Q3 FY27), plus a greenfield expansion at Solapur (465 KL underway). A new R&D facility in Taloja is also under construction, focusing on advanced chemistry. Management projects 10-12% revenue growth for FY27 while maintaining EBITDA margins between 30-32%.